Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results

Simply Wall St.

08/09

ResMed Inc. (NYSE:RMD) came out with its annual results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2658677681"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658677681\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658677681?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-08-09 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658677681","market":"sg","top_or_hot":-1,"title":"Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results","media":"Simply Wall St.","content":"<div>\n<p>ResMed Inc. (NYSE:RMD) came out with its annual results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report.       ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/heres-what-analysts-are-forecasting-for-resmed-inc-nysermd-a\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-09 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/heres-what-analysts-are-forecasting-for-resmed-inc-nysermd-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ResMed Inc. (NYSE:RMD) came out with its annual results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report.       ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/heres-what-analysts-are-forecasting-for-resmed-inc-nysermd-a\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/heres-what-analysts-are-forecasting-for-resmed-inc-nysermd-a","article_id":"2658677681","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/heres-what-analysts-are-forecasting-for-resmed-inc-nysermd-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658677681","pubTimestamp":1786279159,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ResMed Inc. ( NYSE:RMD ) came out with its annual results last week, and we wanted to see how the business is...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","JOYT":"JPMorgan Equity and Options Total Return ETF","BK4548":"巴美列捷福持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","VOTE":"TCW Transform 500 ETF","RGLO":"Global Equity Active ETF","GXDW":"Global X Dorsey Wright Thematic ETF","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","PMDE":"PGIM S&P 500 Max Buffer ETF - December","BK4082":"医疗保健设备","NYSE":"纽交所","BK4504":"桥水持仓","RMD":"瑞思迈","VGFPF":"Vanguard Funds PLC","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC"},"translate_title":"以下是分析师对瑞思迈公司（纽约证券交易所股票代码：RMD）全年业绩公布后的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GXDW":0.69,"JOYT":0.69,"NYSE":1.5,"FEBU":0.69,"LGHT":0.6,"PMDE":0.69,"VOTE":0.69,"RMD":1.5,"DECU":0.69,"VGFPF":0.69,"RGLO":0.69},"content_text":"ResMed Inc. (NYSE:RMD) came out with its annual results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report.       It was a credible result overall, with revenues of US$5.7b and statutory earnings per share of US$10.43 both in line with analyst estimates, showing that ResMed is executing in line with expectations.     The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of.  Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on ResMed after the latest results.  AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NYSE:RMD Earnings and Revenue Growth August 9th 2026 Taking into account the latest results, the consensus forecast from ResMed's 24 analysts is for revenues of US$5.80b in 2027. This reflects a credible 2.6% improvement in revenue compared to the last 12 months.       Statutory earnings per share are predicted to rise 9.1% to US$11.52.        Before this earnings report, the analysts had been forecasting revenues of US$5.84b and earnings per share (EPS) of US$11.35 in 2027.        The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.     Check out our latest analysis for ResMed   There were no changes to revenue or earnings estimates or the price target of US$247, suggesting that the company has met expectations in its recent result.        Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation.   The most optimistic ResMed analyst has a price target of US$325 per share, while the most pessimistic values it at US$175.   This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.      These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the ResMed's past performance and to peers in the same industry. We would highlight that ResMed's revenue growth is expected to slow, with the forecast 2.6% annualised growth rate until the end of 2027 being well below the historical 11% p.a. growth over the last five years.    By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.6% per year.  So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than ResMed.     AdvertisementThe Bottom Line  The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates.        On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry.       The consensus price target held steady at US$247, with the latest estimates not enough to have an impact on their price targets.   Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider.   At Simply Wall St, we have a full range of analyst estimates for ResMed going out to 2029, and you can see them free on our platform here..  We also provide an overview of the ResMed Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock,  here. New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}